UNSPSC 51282923: Grepafloxacin

This classification denotes a quinolone antibiotic with the molecular formula C19H22FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L1M1U2HC31, chemically known as 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo- but generally known as grepafloxacin, which bears US NIH Compound Identifier 72474. European Medicines Agency schedules Grepafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07965MIG.

UNSPSC 51282923 Grepafloxacin, a Commodity code, nominally designates a specific fluoroquinolone antibiotic, but recent state and local opportunities tagged under this code show little demand for grepafloxacin itself. Instead, the recent solicitations under this code span a broader pharmaceutical and medical-supply landscape: Seminole County, Florida is procuring naloxone and drug deactivation systems; the Texas Health and Human Services Commission is gathering market intelligence on direct-to-manufacturer prescription programs; the City of Tampa is sourcing medical and first aid supplies for fire rescue operations; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing statewide contracts for generic multi-source pharmaceuticals and OTC products. The issuing bodies include county health departments, state health agencies, municipal fire services, and interstate cooperative purchasing alliances, reflecting a mix of direct procurement and framework-agreement structures. The work being solicited ranges from tactical consumables (bandages, oxygen delivery systems, respiratory equipment) through strategic pharmaceutical contracting aligned with value-based pricing and supply-chain security.

Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon (through MMCAP participation), with the cooperative-purchasing vehicle enabling participation across multiple states. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, though the posting date is June 30, 2026, suggesting a data error in the source); the Texas HHS RFI on direct-to-manufacturer prescriptions (posted April 3, 2026, with an April 3, 2026 response deadline); the City of Tampa's IFB for medical and first aid supplies (169 line items, due March 13, 2026, estimated value $700,000, sheltered for certified Small Local Business Enterprises with a 5 percent bid discount); and MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026, awarding effective July 1, 2026). The code shows activity but does not reflect strong demand for the grepafloxacin product itself—recent procurement is distributed across multiple pharmaceutical categories and medical-supply classes.